Additional file 1 of Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Additional file 1: Supplemental Methods. Supplemental Figure 1. Genomic landscape of mutations in various cohorts of patients used for the study. Supplemental Figure 2. Quality Control Assessments of RNAseq Data. Supplemental Figure 3. Principal Component (PC) Analyses of QC Data. Supplemental Figure 4. QQ plots of observed and expected results. Supplemental Figure 5. LSC17 score applied to RNAseq data from bulk MNCs and VLBsCD34+. Supplemental Table 1. Genetic Sequencing Data. Supplemental Table 2. RNA Sequencing Data. Supplemental Table 3. QRT-PCR Assays. Supplemental Table 4. Characteristics of included and excluded patients. Supplemental Table 5. Comparisons to assess the impact of batch, instrument, and tissue source on transcript profiles. Supplemental Table 6. Expression changes associated with patient characteristics. Supplemental Table 7. Pathways associated with DEGs and patient characteristics. Supplemental Table 8. Expression changes and pathways associated with clinical outcomes. Supplemental Table 9. Prognostic significance of LSC17 in RNA from MNCs and VLBsCD34+ from the discovery cohort.